Illumina Stock Is Slipping. Biotech Investors Are Hard to Impress.

Text size

Illumina

alerted investors a month ago that it beat Wall Street forecasts for December-quarter sales. After Thursday’s close, the gene-sequencing leader reported its full results for the quarter, and they included a strong earnings beat, as well. Guidance was for moderating growth, however, and in after-hours trading, the stock slipped.

Illumina (ticker:…